Mr. Brent Willis reports

VOYAGEUR ACHIEVES MILESTONE WITH RAIN CAGE ROYALTY AGREEMENT FOR SUSTAINABLE CARBON DRUG DEVELOPMENT

Voyageur Pharmaceuticals Ltd. has achieved a significant advancement in its partnership with Rain Cage Carbon Inc. This milestone signifies the execution of a royalty agreement that solidifies the exclusive development and licence agreement between the parties and it further reinforces Voyageur's commitment to pioneering sustainable carbon drug development.

Brent Willis, chief executive officer of Voyageur, states: "Voyageur is pioneering the development of the world's first carbon-neutral pharmaceutical company. Our groundbreaking carbon drug program may revolutionize the industry, by harnessing captured CO2 as its primary ingredient. This innovative approach not only aligns with sustainable practices but also positions Voyageur as a trailblazer in the radiology drug market through seamless vertical integration. Our Rain Cage partnership is shaping the future of environmentally conscious and cutting-edge pharmaceutical solutions."

Driving innovation in health care imaging

Voyageur and Rain Cage have solidified their strategic alliance and are poised to redefine health care imaging technologies. The execution of the royalty agreement underscores their shared dedication to leveraging Rain Cage's pioneering Eden carbon capture technology for the creation of innovative nanocarbon-/fullerene-based imaging drugs.

Building an ecofriendly drug pipeline

In alignment with its sustainable goals, Voyageur is forging ahead with the establishment of an ecofriendly drug pipeline. This pipeline includes barium sulphate contrast media, iodinated contrast media and carbon contrast media products, forming an integral part of Voyageur's earth to bottle strategic business plan.

Pioneering MRI drug development

With a focus on innovation, Voyageur is spearheading the development of a new MRI (magnetic resonance imaging) drug utilizing the V@C60 molecule. This breakthrough holds promise for revolutionizing MRI imaging as well as facilitating targeted drug delivery of contrast agents to specific areas of the body.

Sustainable carbon production for future growth

Building upon Rain Cage's breakthrough in carbon production from captured carbon dioxide, Voyageur is poised for sustainable growth. The preparation of a carbon production revenue sharing agreement is under way to exploit carbon captured and leverage the cash flow generated by carbon production technology at Voyageur's future pharmaceutical manufacturing facility. Voyageur is evaluating several existing pharmaceutical facilities, to enable the vertical integration of its pharmaceutical projects and align with its vision of integrating sustainability into pharmaceutical production.

Leading the way in pharmaceutical sustainability

Voyageur's partnership with Rain Cage underscores its leadership in sustainable pharmaceutical development. By executing the royalty agreement and advancing ecofriendly drug development, Voyageur is contributing to a healthier future and a greener planet.

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the TSX Venture Exchange, is in development of barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast market, Voyageur aims to become a key player by producing its own barium, iodine and fullerene minerals.

We seek Safe Harbor.